Development
ADMA Biologics, Inc.
ADMA
$18.96
-$0.95-4.77%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 47.86% | 63.72% | 77.33% | 95.56% | 89.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.86% | 63.72% | 77.33% | 95.56% | 89.45% |
| Cost of Revenue | 19.59% | 35.59% | 58.15% | 58.80% | 56.55% |
| Gross Profit | 119.28% | 155.29% | 141.85% | 350.93% | 303.73% |
| SG&A Expenses | -14.55% | -18.36% | -6.36% | -7.82% | 14.39% |
| Depreciation & Amortization | 5.04% | 0.00% | 0.00% | 0.00% | -0.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.48% | 14.84% | 34.16% | 31.44% | 41.61% |
| Operating Income | 334.93% | 200.74% | 125.36% | 94.51% | 54.07% |
| Income Before Tax | -44.25% | 117.22% | 53.72% | 72.85% | 26.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.25% | 117.22% | 53.72% | 72.85% | 26.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.25% | 117.22% | 53.72% | 72.85% | 26.53% |
| EBIT | 334.93% | 200.74% | 125.36% | 94.51% | 54.07% |
| EBITDA | 496.24% | 253.97% | 159.39% | 109.22% | 64.69% |
| EPS Basic | -29.52% | 115.02% | 59.20% | 76.04% | 34.53% |
| Normalized Basic EPS | 162.60% | 119.20% | 77.17% | 67.35% | 34.55% |
| EPS Diluted | -30.59% | 112.50% | 57.20% | 76.04% | 33.98% |
| Normalized Diluted EPS | 162.60% | 118.35% | 77.17% | 67.35% | 34.55% |
| Average Basic Shares Outstanding | 11.41% | 14.71% | 13.41% | 13.30% | 12.18% |
| Average Diluted Shares Outstanding | 11.41% | 19.03% | 13.41% | 13.30% | 12.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |